De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Immuneering Beheer

Beheer criteriumcontroles 3/4

De CEO Immuneering's is Ben Zeskind, benoemd in Feb2008, heeft een ambtstermijn van 16.67 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.92M, bestaande uit 30.9% salaris en 69.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 10.71% van de aandelen van het bedrijf, ter waarde $ 7.91M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.1 jaar en 3.7 jaar.

Belangrijke informatie

Ben Zeskind

Algemeen directeur

US$1.9m

Totale compensatie

Percentage CEO-salaris	30.9%
Dienstverband CEO	16.7yrs
Eigendom CEO	10.7%
Management gemiddelde ambtstermijn	3.1yrs
Gemiddelde ambtstermijn bestuur	3.7yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Ben Zeskind's beloning veranderd ten opzichte van Immuneering's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$56m
Mar 31 2024	n/a	n/a	-US$54m
Dec 31 2023	US$2m	US$593k	-US$53m
Sep 30 2023	n/a	n/a	-US$52m
Jun 30 2023	n/a	n/a	-US$52m
Mar 31 2023	n/a	n/a	-US$51m
Dec 31 2022	US$2m	US$570k	-US$51m
Sep 30 2022	n/a	n/a	-US$48m
Jun 30 2022	n/a	n/a	-US$44m
Mar 31 2022	n/a	n/a	-US$40m
Dec 31 2021	US$2m	US$400k	-US$34m
Sep 30 2021	n/a	n/a	-US$29m
Jun 30 2021	n/a	n/a	-US$24m
Mar 31 2021	n/a	n/a	-US$20m
Dec 31 2020	US$806k	US$293k	-US$17m

Compensatie versus markt: De totale vergoeding ($USD 1.92M ) Ben } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 677.23K ).

Compensatie versus inkomsten: De vergoeding van Ben is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Ben Zeskind (41 yo)

16.7yrs

Tenure

US$1,918,201

Compensatie

Dr. Benjamin J. Zeskind, also known as Ben, Ph D., MBA serves as the Co-Founder, President, Chief Executive Officer and Director of Immuneering Corporation since February 2008 and served as its Secretary....

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Benjamin Zeskind	Co-Founder	16.7yrs	US$1.92m	10.71% $ 7.5m
Robert Carpenter	Co-Founder & Chair Emeritus	16.8yrs	US$202.74k	3.87% $ 2.7m
Brett Hall	Chief Scientific Officer	4.9yrs	US$1.40m	1.17% $ 819.8k
Harold Brakewood	Chief Business Officer	1.6yrs	US$1.57m	0.013% $ 9.2k
Mallory Morales	Principal Financial & Accounting Officer	2.2yrs	geen gegevens	0.043% $ 30.2k
Paula George	Director of Accounting & Operations and Assistant Corporate Controller	3.1yrs	geen gegevens	geen gegevens
Michael Bookman	Chief Legal Officer & Secretary	3.3yrs	geen gegevens	0.013% $ 9.1k
Leah Neufeld	Chief People Officer	2yrs	geen gegevens	0.034% $ 23.8k
Peter King	Head of Discovery & VP	no data	geen gegevens	geen gegevens
Praveen Nair	Head of Translational Pharmacology & VP	2.6yrs	geen gegevens	geen gegevens
Stephen Sebastian	Executive Director & Corporate Controller	3.1yrs	geen gegevens	geen gegevens

3.1yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van IMRX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Benjamin Zeskind	Co-Founder	16.7yrs	US$1.92m	10.71% $ 7.5m
Robert Carpenter	Co-Founder & Chair Emeritus	15.4yrs	US$202.74k	3.87% $ 2.7m
Laurie Keating	Independent Director	3.6yrs	US$179.88k	0.047% $ 33.2k
Douglas Lauffenburger	Co-Chairman of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Peter Feinberg	Director	3.8yrs	US$165.67k	3.7% $ 2.6m
Ann Berman	Independent Chair	3.3yrs	US$181.38k	0.23% $ 159.9k
Diana Hausman	Independent Director	2.8yrs	US$175.38k	0% $ 0
Max Artyomov	Co-Chairman of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Bijan Nejadnik	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Tanios Bekaii-Saab	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Daniel Ahn	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Denis Guttridge	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

3.7yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van IMRX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.7 jaar).

Immuneering Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Immuneering Corporation, Annual General Meeting, Jun 12, 2024

Independent Chair recently bought US$123k worth of stock

Less than half of directors are independent

Immuneering Corporation Appoints Thomas J. Schall to Its Board of Directors

Immuneering Corporation Appoints Mallory Morales as Chief Accounting Officer, Effective July 1, 2023

Immuneering Corporation Appoints Leah R. Neufeld as Chief People Officer

Recent updates

Immuneering Corporation Announces Positive Initial Phase 2A Data Including Complete and Partial Responses with Imm-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Companies Like Immuneering (NASDAQ:IMRX) Could Be Quite Risky

Immuneering Corporation(NasdaqGM:IMRX) dropped from Russell Small Cap Comp Value Index

Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?

Immuneering Corporation, Annual General Meeting, Jun 12, 2024

Immuneering Corporation Presents Preclinical Data At the American Association for Cancer Research Annual Meeting

Immuneering Announces First Patient Dosed in Its Phase 1/2A Trial of Imm-6-415 to Treat Advanced Solid Tumors with Raf or Ras Mutations

Independent Chair recently bought US$123k worth of stock

Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone

Price target decreased by 12% to US$16.86

Immuneering Announces Positive Topline Results from Phase 1 Portion of Its Phase 1/2A Clinical Trial of IMM-1-104 in Ras-Mutant Solid Tumors

New major risk - Share price stability

Less than half of directors are independent

Immuneering Corporation Appoints Thomas J. Schall to Its Board of Directors

Immuneering Doses First Patient in Phase 2A Clinical Trial of IMM-1-104 in Ras-Mutant Solid Tumors

New major risk - Revenue and earnings growth

Immuneering Corporation Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?

New major risk - Share price stability

Third quarter 2023 earnings released: US$0.43 loss per share (vs US$0.49 loss in 3Q 2022)

New minor risk - Share price stability

Immuneering Corporation Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference

We're Not Very Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate

First half 2023 earnings released: US$0.93 loss per share (vs US$0.93 loss in 1H 2022)

Immuneering Corporation Appoints Mallory Morales as Chief Accounting Officer, Effective July 1, 2023

New major risk - Revenue and earnings growth

First quarter 2023 earnings released: US$0.51 loss per share (vs US$0.49 loss in 1Q 2022)

Price target decreased by 12% to US$18.71

Consensus revenue estimates decrease by 80%, EPS upgraded

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$21.33

Immuneering Corporation Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations

Consensus revenue estimates fall by 26%

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Immuneering Corporation Appoints Leah R. Neufeld as Chief People Officer

Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations

Immuneering wins FDA nod to study lead asset in solid tumors

Immuneering Corporation Announces Committee Changes

Consensus forecasts updated

Immuneering Announces Submission of IND Application to the FDA for Phase 1/2A Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations

Immuneering seeks FDA nod to conduct clinical trial for lead cancer candidate

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Immuneering Corporation Announces Management Changes

Immuneering initiated a Buy by Chardan, PT set to $18

Immuneering Corporation(NasdaqGM:IMRX) dropped from Russell 2500 Value Index

Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS/NRAS Activity of IMM-1-104

Consensus forecasts updated

First quarter 2022 earnings: EPS misses analyst expectations

Immuneering Corporation, Annual General Meeting, Jun 21, 2022

Consensus revenue estimates fall by 75%

Full year 2021 earnings: EPS and revenues miss analyst expectations

Immuneering Corporation Reports Preclinical Data on IMM-1-104 in NRAS Mutant Melanoma Model

Immuneering Corporation (NasdaqGM:IMRX) acquired BioArkive, Inc. from Brett Hall, Praveen Nair, Daniel Flynn, Thomas Barr, Anna Travesa and Dennis Garland for $8.5 million.

Third quarter 2021 earnings released: US$0.47 loss per share

Director recently bought US$116k worth of stock

Director recently bought US$131k worth of stock

Less than half of directors are independent

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd